Top 10 Video Interviews of 2024

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

The editors of BioPharm International® had the fortunate opportunity to sit down with several subject matter experts from the biopharmaceutical industry in 2024, with topics ranging from cell and gene therapies, messenger RNA, quality management, bispecific antibodies, and more.

The following are some of our most watched video interviews from 2024:

• Improving the Sensitivity and Action of CAR-T Cell Therapies (ASGCT 2024)
  Regeneron’s work in chimeric antigen receptor (CAR)-T cell therapy development includes engineering receptor architecture to improve CAR-T cell sensitivity and improve immune response.
  https://www.biopharminternational.com/view/improving-the-sensitivity-and-action-of-car-t-cell-therapies-asgct-2024-
• Advancing Delivery of AAV Vector-Based Gene Therapies Using Bispecific Antibodies (ASGCT 2024)
  Sven Moller-Tank, PhD, director of Viral Delivery Technologies, Regeneron Genetic Medicines, Regeneron spoke about the use of bispecific antibodies to retarget adeno-associated virus (AAV) specificity.
  https://www.biopharminternational.com/view/advancing-delivery-of-aav-vector-based-gene-therapies-using-bispecific-antibodies-asgct-2024-
• BIO 2024: Robotics in Sterile Processing
  BioPharm International® spoke with Jeff Clement, executive director of Technical Sales for Development and Manufacturing Group at PCI Pharma Services, about the challenges and benefits of incorporating robotics into aseptic manufacturing.
  https://www.biopharminternational.com/view/bio-2024-robotics-in-sterile-processing
• Exploring How Chemistry, Robotics, and AI are Advancing Drug Discovery (BIO 2024)
  Chemify founder and CEO, Lee Cronin gives insight into the combination of digital chemistry, robotics, and AI in the drug discovery process.
  https://www.biopharminternational.com/view/exploring-how-chemistry-robotics-and-ai-are-advancing-drug-discovery-bio-2024-
• BIO 2024: Impact of Biosecure Act on the Pharma Industry
  Parviz Shamlou, senior vice-president of Science and Technology, Abzena, talks about the impact of the Biosecure Act on the bio/pharmaceutical industry, as well as the progress of continuous manufacturing in biopharma.
  https://www.biopharminternational.com/view/bio-2024-impact-of-biosecure-act-on-the-pharma-industry
• Industry Tackles Automating and Standardizing CGT Manufacturing Processes (BIO 2024)
  Cell and gene therapy (CGT) manufacturing processes need automation as well as standardization, according to Lonza’s Joe Garrity and Jerry Jiang.
  https://www.biopharminternational.com/view/industry-tackles-automating-and-standardizing-cgt-manufacturing-processes-bio-2024-
• Quality Considerations in Changing Excipient Providers
  In the premiere episode of the Ask the Expert video series, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, vice president, Technical at Parexel, discuss the challenges involved in changing an excipient supplier.
  https://www.biopharminternational.com/view/quality-considerations-in-changing-excipient-providers
• A Look at the Outsourcing Landscape for mRNA (BIO 2024)
  Christian Cobaugh, CEO and founder of Vernal Biosciences, considers the outsourcing landscape for mRNA production.
  https://www.biopharminternational.com/view/a-look-at-the-outsourcing-landscape-for-mrna-bio-2024-
• Susan Schniepp of Regulatory Compliance Associates Discusses the Impact of QMS on Quality Maturity at INTERPHEX 2024
  At INTERPHEX 2024, Susan Schniepp, distinguished fellow, Regulatory Compliance Associates, and co-chair of board of directors, Parenteral Drug Association, explores the impact of quality management system (QMS) on quality maturity.
  https://www.biopharminternational.com/view/susan-schniepp-of-regulatory-compliance-associates-discusses-the-impact-of-qms-on-quality-maturity-at-interphex-2024
• Exploring the Use of AI in R&D at the US Pharma and Biotech Summit
  Regeneron’s Bari Kowal, senior vice-president, head Development Operations & Portfolio Management, gave insight into how the biopharma industry views the application of artificial intelligence (AI) in R&D.
  https://www.biopharminternational.com/view/exploring-the-use-of-ai-in-r-d-at-the-us-pharma-and-biotech-summit

For more video interviews, visit BioPharmInternational.com. Check back throughout 2025 for the latest conference coverage. In addition, our Ask the Expert video series can be found at https://www.biopharminternational.com/topic/ask-the-expert.